What is the name of the methodology?
FUN-TRACE: FUNseq-based TRAnscriptional and Chromatin Exploration profiling
OI Name
Miao-Ping Chien group
What is the methodology good for?
The method integrates live-cell imaging with single-cell transcriptomic and epigenomic profiling to characterize dynamic cellular behaviors and phenotypes
What is/are the main advantages of this methodology over related technologies?
FUN-TRACE integrates imaging and multi-omics modalities, specifically linking cellular behaviors and phenotypes to their corresponding transcriptomic and epigenomic states. Many state-of-the-art multi-omics approaches still lack the integration of complex imaging data.
What are the most important limitations of the methodology?
The pipeline is quite complex and involves multiple components, including imaging and multi-omics library preparation.
What type of samples are compatible with methodology?
Cancer cell lines | Primary cells in culture | Organoids | Primary tissue |
Yes | Yes | possibly | possibly |
What future develops to the methodology are you planning, in any?
We plan to incorporate additional epigenomic modalities (e.g., CUT&RUN) beyond the currently used ATAC-seq profiling and extend the approach to 3D samples.
If someone outside your lab wants to use the methodology, what is the best option?
As mentioned, the pipeline is quite complex; therefore, it is best to contact and collaborate with us.
Name one or more people in your lab that are experienced with the methodology
Toba Ajani, Reza Ghadiri Rad and Maria Lopez-Cascales
Who originally developed the methodology?
FUN-TRACE is being developed by the Miao-Ping Chien group, led by Toba Ajani and Reza Ghadiri Rad. It is still unpublished.
Additional information to provide:
- Lead:
FUN-TRACE bridges live-cell imaging and multi-omics to reveal how dynamic cellular behaviors are encoded in transcriptional and chromatin states.
- Quote:
With FUN-TRACE, we are now studying how cancer cells respond to radiation in real time and revealing the transcriptional and epigenomic programs behind therapy response.